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The role of allorecognition in initiating lung graft rejection is not the pathology of human OB (2). Studies have validated the
clearly defined. Using the heterotopic tracheal transplantation use of the mouse heterotopic tracheal transplant model and
model, we examined the contributions of the indirect and direct yielded important initial observations showing that alloim-
allorecognition pathways in chronic airway rejection. Fully mis- mune injury that leads to OB (3–8).
matched, wild-type grafts were transplanted into major histocom- The initial and central event that ultimately leads to graft
patibility complex (MHC) II/, class II-like accessory molecule (H2- rejection is allorecognition. Allospecific T cells may be acti-
DM)/ using MHC I/ and wild-type allorecipients as control vated by two distinct pathways (9–13). The direct pathway
subjects. Similarly, MHC I/, MHC II/, or MHC I/II/ allografts is defined by the allorestricted activation of recipient T cells
were transplanted into wild-type mice with appropriate control by donor antigen-presenting cells, whereas the indirect path-subjects. Grafts from nonimmunosuppressed recipients were evalu-
way refers to activation of recipient T cells through the inter-ated at Weeks 2, 4, and 6. Grafts transplanted into MHC II/ and
action with preprocessed allopeptides presented by recipientH2-DM/ allorecipients showed a more intact epithelium and
antigen-presenting cells in a self major histocompatibilityreduced lumen obliteration compared with grafts transplanted into
complex (MHC) II–restricted manner. Although the mecha-wild-type or MHC I/ allorecipients (p  0.05 for each). These
nism for indirect allorecognition is similar to the physiologicgrafts exhibited abundant CD4 and CD8 cell infiltrates similar
mechanism of host defense, the mechanism of direct allorec-to control allografts. MHC I/ and MHC I/II/ but not MHC II/
ognition pathway is less well characterized. Overall, the rela-allografts placed in wild-type animals demonstrated less severe re-
jection compared with allograft control subjects (p  0.05 for each). tive contributions of the indirect and direct allorecognition
Although the indirect allorecognition pathway has the strongest pathways to organ graft rejection remain largely unknown
influence on rejection, the direct pathway is sufficient to ultimately and have not been well studied in the tracheal transplant
cause chronic airway rejection. In addition, these results suggest model.
that MHC class I molecules are the principal alloantigens in the Genetically engineered mice have been generated and
mouse heterotopic tracheal model of obliterative bronchiolitis. used to examine the biologic function of components of the
antigen processing pathway. The MHC class II molecules
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are heterodimers consisting of  and  chains, which areplant model; obliterative bronchiolitis
assembled in the endoplasmic reticulum, associated with the
invariant chain and transported into the endosomal compart-Lung transplantation has become a successful clinical therapy
ment where the invariant chain is proteolytically degradedfor individuals with diverse end-stage pulmonary diseases.
into class II-associated invariant chain peptide (CLIP). TheDespite advances in several aspects of pulmonary transplant
class II-like accessory molecule HLA-DM or its murinemedicine, chronic lung allograft rejection, manifested as pro-
equivalent, H2-DM, catalyzes the dissociation of CLIP andgressive airway obstruction, namely obliterative bronchiolitis
assists in the loading of the antigenic peptides, thereby play-(OB), remains the leading cause of morbidity and mortality
ing an important role in the orderly trafficking of MHC II-among long-term survivors of lung transplantation (1). The
peptide complexes to the cell surface. Mice deficient in MHCtreatment of OB is ineffective, mainly because of our lack
class II expression have been generated by deleting the Aof knowledge of the pathogenesis of this disease. In the mouse
gene, resulting in undetectable MHC class II expression (14,heterotopic tracheal transplant model, allografts, but not iso-
15). Mice deficient in MHC class I expression have also beengrafts, develop a defined, predictable succession of airway
generated by disruption of the gene encoding the 2-micro-inflammation, epithelial injury and denudation, and lumen
globulin, a polypeptide required for proper assembly and cellfibroproliferation, resulting in airway obliteration replicating
surface expression of MHC class I molecules (16, 17). In
addition, mice deficient in H2-DM have been generated by
disruption of the H2-DM gene, which encodes the  subunit
for H2-DM. In the absence of H2-DM, CLIP cannot be
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H2d mice were transplanted into fully mismatched MHC I/, MHCthe absence of CD4 T cell “help” (26–28), resulting in
II/, H2-DM/, and wild-type H2b mice. For isograft control subjects,rejection (26, 27). Therefore, the use of MHC II-deficient
tracheae from wild-type H2b were transplanted into wild-type H2b mice.grafts cannot entirely exclude direct (MHC I-dependent) al-
Second, tracheal grafts were obtained from MHC I/, MHC II/,lorecognition (24, 25). In the experiments described herein,
MHC I/II/, and wild-type H2b or H2d mice and placed into wild-typewe pursued an alternative and comprehensive approach to
H2d mice. All mice were maintained following the National Institutesevaluate the role and contribution of each allorecognition of Health guidelines for the care and use of laboratory animals under
pathway and donor MHC molecules in lung transplant rejec- specific pathogen-free conditions.
tion. First, we transplanted wild-type tracheal allografts into
MHC II/ or H2-DM/ mice, which have different disrup- Mouse Heterotopic Tracheal Transplantation
tions in the class II-dependent antigen presentation process As previously described (4–6), tracheae were transplanted into a subcu-
that, in effect, eliminates indirect allorecognition. Second, taneous pocket behind the neck of the recipient after anesthesia was
we transplanted MHC I-, II-, and I/II-deficient allografts into achieved by injecting Domitor (5 mg/kg)/Ketamine (100 mg/kg) (Divi-
wild-type recipients to assess the role of MHC I and MHC sion of Laboratory Animal Medicine, UNC) intraperitoneally and then
II-mediated direct allorecognition and MHC molecules as reversed with Antisedan (2.5 mg/kg) (Division of Laboratory Animal




Mice and Study Design Grafts were harvested at Weeks 2, 4, and 6. Tissue processing, staining,
and image acquisition have been previously described (4–6). Detach-The following female mice between 8 and 12 weeks of age were used:
ment of the differentiated (ciliated) epithelium (epithelial injury) andwild-type BALB/c (H2d) and C57BL/6 (H2b) (Harlan Labs, Indianapo-
lumen obliteration (fibroproliferation) were examined to determinelis, IN), H2b MHC class I deficient (MHC I/) (17), H2b MHC class
airway rejection. The intact differentiated epithelium and total airwayII deficient (MHC II/) (14), and H2b MHC class I and II deficient
circumference were measured at the level of the sub-basement mem-(MHC I/II/) (29) (Taconic Labs, Germantown, NY). In addition, H2-
brane. Quantitation of the epithelialization and fibroproliferation wasDM/ mice were backcrossed onto the H2b background for nine
performed using the Metamorph Image analysis program (West Ches-generations and were bred and maintained at the University of North
Carolina at Chapel Hill (UNC) (18). First, allografts from wild-type ter, PA) by three independent, blinded reviewers and was expressed
Figure 1. Histopathology of wild-
type H2d tracheal grafts trans-
planted into wild-type, MHC-, or
H2-DM–deficient H2b allore-
cipients at Weeks 2 (10 and
40) and 4 (10) (hematoxylin
and eosin). Tracheal grafts trans-
planted into wild-type allorecip-
ients (A–C ), but not wild-type
isorecipients (D–F ), showed a suc-
cessive loss of intact, ciliated epi-
thelium, and diminished lumen
patency, eventuating in complete
airway obliteration by Week 4.
Grafts transplanted into MHC
II/ (G–I ) and H2-DM/ ( J–L),
but not MHC I/ (M–O), showed
significantly less severe chronic
airway rejection. E  epithelium,
L  airway lumen, C  tracheal
cartilage.
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as the fraction of total airway circumference or of the total lumen cross-
sectional area, respectively (4–6).
Immunohistochemistry
Frozen sections were air dried, fixed in chilled acetone, and blocked
with 5% normal goat serum (Jackson ImmunoResearch, West Grove,
PA) and avidin-biotin block (Vector Labs, Burlingame, CA). The sec-
tions were incubated with monoclonal rat anti-mouse CD4 or CD8
antibodies, then biotinylated goat anti-rat antibody, and finally streptav-
idin-horseradish-peroxidase (Pharmingen, San Diego, CA). Optimal
dilutions and incubation periods were determined empirically. Dupli-
cate sections on the same slide were incubated with rat IgG2a (Jackson
ImmunoResearch) as a negative isotype control. The diaminobenzidine
substrate (Sigma, St. Louis, MO) was used, and sections were counter-
stained with Light Green (Fisher Scientific Co., Pittsburgh, PA). Cells
were counted within the area outlined by an equidistant line, 10 m
outward from the sub-basement membrane. In accordance with the
previously described profile of immune cellular infiltration into allo-
grafts in this model (4), grafts were examined for CD4 and CD8 T
cells at Week 2.
Statistical Analysis
Analyses were performed using SigmaStat software (SPSS Inc., Chi-
cago, IL). Parameters were compared at each time point using the
student’s t-test. A two-tailed  level of p  0.05 was considered signifi-
cant. Repeated-measures analyses of variance were used (8) to confirm
the results from the t-test analyses.
RESULTS
Allogeneic Transplantation into Fully Mismatched, Wild-type
H2b or H2d Mice
The wild-type H2d and H2b tracheal isografts showed a complete,
intact, fully differentiated epithelium and patent lumen at 2, 4,
and 6 weeks (n  4, at each time point for both arms; Figures
1 and 2). Therefore, the initial ischemic insult by itself had no
impact on the subsequent repair of the epithelium or the OB
in this transplant model. Figure 2. Airway rejection in wild-type (WT) grafts transplanted into
At 2, 4 and 6 weeks, the allografts (wild-type H2d grafts wild-type, MHC-, or H2-DM–deficient recipients is shown as (A ) the
transplanted into fully mismatched, wild-type H2b recipients, n  mean percentage of intact ciliated airway epithelium and (B ) the mean
3 to 4, at each time point) had less intact, fully differentiated percentage of airway lumen patency. *Comparisons (p  0.05) between
(ciliated) epithelium compared with the isografts (wild-type H2b the control allografts and the control isografts at the same time point.
grafts transplanted into wild-type isorecipients, n  4, at each **Comparisons (p  0.05) between the experimental arms and the
time point) (p  0.03, p  0.001, and p  0.001, respectively; control allografts placed in wild-type recipients at the same time point.
Figures 1 and 2A). After epithelial denudation, the lumen of Grafts transplanted into MHC II- and H2-DM–deficient allorecipients,
but not grafts transplanted into MHC I–deficient allorecipients, showedthe allografts displayed markedly decreased patency compared
significantly less epithelial denudation and airway obliteration from 2with the isografts (n  3, p  0.002 at 4 weeks, and n  4, p 
to 6 weeks when compared with grafts transplanted into wild-type0.001 at 6 weeks; Figures 1 and 2B).
recipients.Similar results were seen in wild-type H2b allografts trans-
planted into wild-type H2d recipients as compared with H2d
allografts transplanted into wild-type H2b recipients (n  3 to weeks, wild-type grafts transplanted into fully mismatched MHC
5, each arm and time point; p 	 0.005 for ciliated epithelium at II/ allorecipients (n  3) underwent epithelial denudation and
2, 4, and 6 weeks and p  0.005 for lumen patency at 4 or 6 lumen obliteration similar to wild-type grafts transplanted into
weeks; Figures 5, 6A, and 6B), which reproduced the results from wild-type allorecipients (p 
 0.2 each; Figures 1, 2A, and 2B).
previous studies (3–8). Therefore, we demonstrated a uniform Allogeneic transplantation into fully mismatched, H2-DMa–
profile of airway rejection across two strains of mouse recipients. deficient mice. At 2 weeks, wild-type grafts transplanted into
H2-DM/ allorecipients (n  6) had more intact ciliated epi-
Testing the Indirect Pathway of Allorecognition
thelium than those transplanted into wild-type allorecipients
Allogeneic transplantation into fully mismatched, MHC II-defi- (p  0.007). There was no lumen obliteration (Figures 1, 2A,
cient mice. At 2 weeks, wild-type grafts transplanted into fully and 2B). At 4 weeks, wild-type grafts transplanted H2-DM/
mismatched MHC II/ allorecipients (n  4) had more intact, allorecipients (n  6) showed significantly more intact, ciliated
ciliated epithelium than those transplanted into wild-type allore- epithelium (p  0.005) and more airway lumen patency (p 
cipients (p  0.01). There was no lumen obliteration observed 0.001) than grafts transplanted into wild-type allorecipients. At
in any of the grafts (Figures 1, 2A, and 2B). At 4 weeks, wild- 6 weeks, wild-type grafts transplanted into H2-DM/ allore-
type grafts transplanted into fully mismatched MHC II/ allore- cipients (n  4) showed epithelial loss similar to wild-type trans-
cipients (n  4) had significantly more intact ciliated epithelium planted into wild-type allorecipients (p 
 0.2; Figure 2A); how-
(p  0.04) and more airway lumen patency (p  0.005) than ever, they showed significantly less lumen obliteration (p  0.05;
Figures 1, 2A, and 2B).wild-type grafts transplanted into wild-type allorecipients. At 6
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Figure 3. Immunohistochemical
staining for CD4 (A–E ) and
CD8 (F–J ) cells in wild-type tra-
cheal grafts transplanted into
MHC- or H2-DM–deficient allo-
recipients at 2 weeks. Magnifica-
tion 40. E  epithelium, L 
airway lumen, C  tracheal carti-
lage.
Allogeneic transplantation into fully mismatched, MHC I-defi- as compared with the wild-type grafts transplanted into isoreci-
pients (n  3) (CD4: 109  56.3 versus 23  12.1, p  0.01;cient mice. At 2, 4, and 6 weeks (n  4 for each), wild-type grafts
transplanted into MHC I/ allorecipients showed a similar CD8: 230.7  25.7 versus 16  6.1, p  0.001; Figures 3 and
4A). Trends toward higher mean CD4 cell counts were foundamount of intact, ciliated epithelium and lumen obliteration as
wild-type grafts transplanted into wild-type allorecipients (p  in wild-type grafts transplanted into MHC I/  (n  5), H2-
DM/ (n  4), and MHC II/ allorecipients (n  6) in com-0.1 for ciliated epithelium and lumen obliteration at each time
point; Figures 1, 2A, and 2B). parison to wild-type grafts transplanted into wild-type allorecipi-
ents (p  0.07, p  0.09, and p  0.13, respectively; Figures 3Graft-infiltrating lymphocytes in wild-type grafts transplanted
into fully mismatched, MHC- and H2-DMa–deficient mice. As and 4A). A similar mean CD8 cell count was observed in
wild-type grafts transplanted into MHC II/ and H2-DM/expected, the wild-type grafts transplanted into wild-type alloge-
neic recipients (n  6) had more CD4 and CD8 lymphocytes allorecipients when compared with wild-type grafts transplanted
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tion compared with wild-type allografts (p  0.05 and p  0.004,
respectively). By 6 weeks, MHC I/ allografts (n  5) developed
lumen obliteration similar to wild-type allografts (n  4, p 
0.2 for each; Figures 5, 6A, and 6B).
Transplantation of MHC I/II/ tracheal allografts into fully
mismatched, wild-type mice. At 2 weeks, MHC I/II/ allografts
(n  4) had more intact ciliated epithelium than wild-type allo-
grafts (p  0.05) and did not develop lumen obliteration. At
Week 4, MHC I/II/ allografts (n  6) had more intact ciliated
epithelium and less lumen obliteration compared with wild-type
allografts (p  0.04 and p  0.006, respectively). At Week 6,
although MHC I/II/ allografts (n  6) lost their intact ciliated
epithelium resembling wild-type allografts (p  0.2), they
showed significantly less airway lumen obliteration compared
with wild-type (p  0.04), MHC I/ (p  0.04), or MHC II/
(p  0.05) allografts (Figures 5, 6A, and 6B).
Graft-infiltrating lymphocytes in MHC-deficient allografts.
Wild-type allografts transplanted into wild-type H2d mice (n 
5) showed an abundance of CD4 and CD8 cells compared
with isografts (99  10.4 versus 23  7.5, p  0.001, and 191 
104.5 versus 16  5.1, p  0.01, respectively; Figure 4B). MHC
I/, II/, and I/II/ allografts placed in wild-type mice had a
trend toward higher CD4 (p  0.14, p  0.07, and p  0.2,
respectively) and CD8 (p  0.17, p  0.06, and p  0.17,
respectively) cells when compared with wild-type allografts
(Figure 4B).
DISCUSSION
In this study, we report on the hierarchical importance of the
indirect alloantigen recognition pathway over the direct pathway
in the mouse model of chronic airway rejection. First, in the
presence of the direct allorecognition pathway, we showed that
the disruption of the indirect allorecognition pathway usingFigure 4. The mean number ( SD) of graft-infiltrating CD4 and
MHC II/ or H2-DM/ recipient mice, which lack cell surfaceCD8 lymphocytes: (A ) wild-type grafts transplanted into MHC- or
MHC II molecules or have disrupted loading of peptide antigens,H2-DM–deficient allorecipients. H2-DM/ and MHC II/ mice
respectively, led to less chronic airway rejection. Because equalshowed similar numbers of allograft-infiltrating CD4 and CD8 lym-
or greater numbers of allograft-infiltrating CD4 and CD8 Tphocytes in comparison to the control allografts (p  0.05, each). A
lower mean CD8 cell count was observed in wild-type grafts trans- lymphocytes were found in wild-type allografts transplanted into
planted into MHC I/ mice (p  0.01). (B ) MHC-deficient allografts H2-DM/, and to our surprise, MHC II/ recipients (com-
transplanted into wild-type allorecipients. MHC I/, II/, and I/II/ pared with wild-type control allografts), the attenuation of rejec-
allografts showed trends toward higher numbers of CD4 and CD8 tion was not due to the inability of the recipient’s T lymphocytes
infiltrating cells when compared with the control allografts (p  0.05, to access these grafts. Second, in the presence of the indirect
each). Bracketed p values show comparisons between the experimental pathway, MHC II/ allografts (and passenger leukocytes),
arms or the control isografts with the control allografts. *Comparisons which lack the exogenous (MHC II-mediated) direct allorecogni-
(p  0.05) between the experimental arms and the control isografts. tion pathway, developed chronic rejection in the same manner
WT  wild type. as control allografts. Third, because MHC I- and MHC I/II-
deficient allografts placed into wild-type animals showed dimin-
ished rejection, MHC I peptides are important alloantigens in
this model of chronic lung rejection. Endogenous (MHC I-medi-into wild-type allorecipients (p  0.08 and p  0.2, respectively).
ated) direct allorecognition was not directly tested in this modelA lower mean CD8 cell count was observed in wild-type grafts
but, if present, is a less important pathway based on the findingtransplanted into MHC I/ mice (p  0.001; Figures 3 and 4A).
that wild-type grafts are rejected more slowly in recipients who
Testing the Direct Pathway of Allorecognition and the Role have impaired indirect allorecognition (but intact MHC I direct
of Donor MHC Molecules allorecognition). Finally, the fact that MHC I/II/ grafts were
eventually rejected suggested that non-MHC antigens (e.g., mi-Transplantation of MHC II/ tracheal allografts into fully mis-
nor histocompatibility antigens) were sufficient to cause chronicmatched, wild-type mice. At each time point (n  5 for each),
rejection through the indirect pathway in this model.the MHC II/ allografts had a similar amount of ciliated epithe-
The absence of indirect allorecognition pathway did not leadlium and lumen obliteration as the wild-type allografts (p  0.2
to indefinite survival of fully MHC-mismatched airway allograftsfor ciliated epithelium or lumen obliteration at each time point;
as grafts placed into MHC II/ and H2-DM/ mice but dis-Figures 5, 6A, and 6B).
played a 2-week delay in epithelial denudation and lumen oblit-Transplantation of MHC I/ tracheal allografts into fully mis-
eration (Figure 2). This observation maybe explained by the factmatched, wild-type mice. At 2 weeks, MHC I/ allografts (n 
that the direct allorecognition pathway, which triggers a less5) had more ciliated epithelium than wild-type allografts (p 
robust alloimmune response, was sufficient to result in complete0.05) and no lumen obliteration. At 4 weeks, these grafts (n  7)
showed more intact ciliated epithelium and less lumen oblitera- airway allograft rejection at a slower pace. In addition, the equal
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Figure 5. Histopathology of
wild-type, MHC-deficient H2b
tracheal allografts transplanted
into wild-type H2d recipients at
Weeks 2 (10 and 40) and 4
(10) (hematoxylin and eo-
sin). An identical profile of air-
way rejection was observed in
wild-type H2b allografts trans-
planted into wild-type H2d re-
cipients (A–C ) in comparison
with that in wild-type H2d allo-
grafts transplanted into wild-
type H2b recipients (Figures
1A–1C). MHC I (G–I ) and I/II/
(M–O) but not MHC II/ ( J–L)
allografts showed significantly
less severe chronic airway rejec-
tion. E  epithelium, L  airway
lumen, C  tracheal cartilage.
or greater numbers of infiltrating lymphocytes in these grafts allografts in a pattern similar to MHC II/ mice confirms the
importance of the indirect allorecognition and antigenic peptidecompared with wild-type allografts may signify weaker donor
specificities, a characteristic of direct allorecognition (30). Alter- loading processes in mediating airway allograft rejection. Our
results are also consistent with human studies, which have re-natively, cross-presentation of antigens (occurring with MHC
II/ and H2-DM/ antigen-presenting cells to recipient ported indirect evidence for the importance of the indirect allo-
recognition in OB (34–37) and with animal models (38–40) andCD8 T cells via MHC I molecules) may be responsible for
this late rejection. However, this form of indirect allorecognition human studies (41, 42) showing the importance of the indirect
pathway in other organ transplants. In addition, our findings helpis almost certainly inconsequential in our experiments, as fully
MHC-mismatched grafts were used. Therefore, recipient CD8 explain the previous contradictory results showing that either the
direct (43) or indirect (44) pathway may cause chronic airwayT cells sensitized by allopeptides in the context of recipient MHC
I molecules will not find such determinants on the donor grafts. rejection in the murine tracheal transplant model by demonstra-
ting that each pathway contributes in a different way.MHC II/ mice, due to deficient thymic selection of CD4
T cells during embryonic development, have limited T-cell reper- Previous studies, using MHC-deficient grafts, have demon-
strated the importance of MHC I molecules in pancreatic trans-toires and very low numbers of resting and stimulated CD4
lymphocytes (14, 15). In these mice, deficient T-cell populations, plantation (45, 46), MHC II molecules in heart transplantation
(47), and both MHC I and II molecules in skin transplantationrather than abnormal antigen processing, might have attenuated
the rejection process that we and others (14, 15) have observed. (24, 29). Although the MHC molecules expressed on the graft
may function as alloantigens, they may also participate in theIn contrast, H2-DM/ mice have slightly reduced numbers of
CD4 lymphocytes in the lymph nodes and spleens, but express direct allorecognition pathway as antigen-presenting molecules.
Therefore, efforts to understand the importance of MHC alloan-a very diverse T cell receptor repertoire, quite similar to that of
wild-type animals (18–21, 31, 32). In addition, H2-DM/ CD4 tigens in previous studies using MHC/ grafts only (and not
using MHC/ hosts) may have been confounded by the variablelymphocytes display an allogeneic proliferative response (18–21,
31, 33) and cytokine production (33) not different from wild- importance of direct allorecognition among different organ trans-
plants and vice versa (24, 25). By using MHC-deficient mice astype mice. Therefore, the result of H2-DM/ mice rejecting
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MHC I/ and MHC I/II/ tracheal grafts (17, 52, 53). Likewise,
although H2-DM/ mice express predominantly surface self
CLIP-bound (and not allopeptide-bound) MHC II molecules,
not all cell surface MHC II molecules are bound to CLIP (32,
54). However, the significance of non–CLIP-bound MHC II in
graft rejection is not clear (18). In addition, the mechanism of
H2-DM–dependent peptide loading is allele specific. The ex-
change of CLIP for allopeptides in H2-Ab mice that we employed
is highly dependent on H2-DM expression in comparison to any
other mouse strains (e.g., H2-Ak, H2-Ad) (21–23). Third, because
the pretransplant and post-transplant graft-specific microenvi-
ronment may account for the different contributions of allorec-
ognition pathways among organ transplants and models, the
result in this lung transplant model may not be applicable to
others and requires further investigation. Finally, the effect of
immunosuppressants used in clinical transplant, which may have
different influences on direct and indirect alloreacitivity, was not
tested here. We are making plans to include immunosuppres-
sants in future experiments.
In conclusion, this comprehensive study of alloantigen recog-
nition in the mouse heterotopic tracheal transplant model dem-
onstrated a hierarchical order of allorecognition pathways for
initiating chronic airway rejection. Although the indirect allorec-
ognition pathway is more important, the significance of both
allorecognition pathways should be taken into consideration
when developing strategies to protect recipients from allograft
rejection. This is the first study that takes advantage of H2-
DM/ mice to demonstrate the importance of the allopeptide
loading process in indirect recognition in lung transplant rejec-
tion. In addition, we demonstrated that MHC class I molecules
are the principle alloantigens triggering rejection in the mouse
model of OB, whereas MHC II and minor antigens are likely
to play a less important role. Further studies in other models,
as well as in the clinical arena, are essential to confirm these
findings. Studies to assess the donor-directed specificities of air-
Figure 6. Airway rejection in wild-type (WT), MHC-deficient tracheal way graft-infiltrating lymphocytes are also necessary and are
allografts transplanted into wild-type allorecipients, shown as (A ) the under current investigation.
mean percentage of intact ciliated airway epithelium and (B ) the mean
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